VivoSeq
Other

R/R B-NHL

0

Pipeline Programs↗

3

Active Trials↗

1

Companies Involved↗

R/R B-NHL is an early-stage landscape with 0 programs across 1 company. The most active players are Shanghai Longyao Biotechnology Inc., Ltd..

Intelligence

Pipeline Metrics

Competitive Density

14/100

Pipeline Velocity

0/100

Mech. Concentration

N/A

Completion Rate

N/A

Attrition Rate

0/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

S

Shanghai Longyao Biotechnology Inc., Ltd.

0 programs

Preclinical

Pipeline

Programs by Phase

No pipeline programs currently tracked for this disease.

Analysis

Trial Status

5

clinical trials

Recruiting3 · 60%
Unknown status2 · 40%

Clinical Trials

Trial Activity

CAR-T for R/R B-NHL
Unknown status·TThe First Affiliated Hospital of Soochow University·Phase 2·NCT03196830·10 enrolled
A Combination Study of CAR-T Therapy in r/r B-NHL
Unknown status·RRuijin Hospital·Phase 2·NCT05871684·48 enrolled
One Trial to Evaluate the Safety, Tolerability and Efficacy of JCXH-213 in Patients With r/r B-NHL
Recruiting·—·N/A·NCT06618313·8 enrolled
An Evaluation of LY007 Cell Injection for r/r B-NHL
Recruiting·SShanghai Longyao Biotechnology Inc., Ltd.·Phase 1·NCT06279611·18 enrolled
An Evaluation of LY007 Cell Injection for r/r B-NHL
Recruiting·RRuijin Hospital·Phase 1·NCT06364852·18 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)